Emily Salmini

[Oncogene] Researchers unveiled a novel epigenetic pathway orchestrated by protein arginine methyltransferase 5 (PRMT5) that converges on the functional modulation of chromobox homolog 8 (CBX8) to synchronously governs CD8⁺ T cell exclusion and tumor stemness.

[Communications Biology] Investigators identified a pivotal epitranscriptomic-metabolic axis implicated in breast CSC (BCSC) maintenance. Denetic depletion of either YTHDF1 or squalene epoxidase (SQLE) impairs core BCSC properties and reduces expression of cancer stem cell markers in vivo.

[SUNY Upstate Medical University] Immunologist Dr. Mobin Karimi has been awarded a $3.3 million grant to explore a new type of immunotherapy to treat acute myeloid leukemia. The grant comes from the National Cancer Institute of the National Institutes of Health.

[Naunyn-Schmiedebergs Archives of Pharmacology] Scientists explored the potential of psoralidin to target cervical cancer-CSCs. Molecular docking (MD) and MD simulation was conducted to analyze the interaction of psoralidin with core stemness markers Oct4, Sox2, and Nanog and stability of interaction, respectively.

[Cell Stem Cell] Multi-omics and functional assays revealed that diffuse midline gliomas (DMGs) maintain oligodendrocyte precursor cell (OPC) stemness by dysregulating ACTIVIN signaling. To target stemness, researchers conducted an intrathecal drug screening and identified triple intrathecal therapy as a potent regimen against DMGs.

[Biomaterials Science] Investigators engineered an injectable in situ-forming gelatin hydrogel capable of the sustained, localized co-delivery of resveratrol and salinomycin, thereby simultaneously targeting both cancer cells and breast CSCs.